Survival prognosis and clinical experience of HeartCon-type left ventricular assist device implantation for treating patients with end-stage heart failure: a single-center retrospective study from China
The study indicates that the domestically produced HeartCon-type LVAD in China has a definite, satisfactory therapeutic effect in the treatment of ESHF, which provides a new effective and safe treatment option for ESHF patients that allows quality of life improvement, successful bridging to HTx, and potential long-term survival.
Authors
- Shifu Wang (ORCID: https://orcid.org/0000-0002-2131-9518)
- Yongde Wang
- Yunqiang Zhang (ORCID: https://orcid.org/0000-0001-8668-1182)
- Zhengqing Wang
- Jianming Li (ORCID: https://orcid.org/0000-0002-5012-0989)
- Shutang Ren
- Kegang Jia
- Xiujuan Zhang (ORCID: https://orcid.org/0000-0002-3244-9449)
- Xiao‐Cheng Liu (ORCID: https://orcid.org/0000-0003-2931-1331)
- Ying Yu (ORCID: https://orcid.org/0009-0003-0449-1169)
- Wei Wang (ORCID: https://orcid.org/0000-0003-2044-6387)
Institutions
- TEDA International Cardiovascular Hospital (CN)
Publication Details
- Journal
- Journal of Thoracic Disease
- Published
- 2025-10-01
- DOI
- https://doi.org/10.21037/jtd-2025-810
- Primary Topic
- Mechanical Circulatory Support Devices
- Type
- article
- Field-Weighted Citation Impact
- 0.00